Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Lilly Had Big Ambitions For Tanezumab; Are They Finally Dashed?

Executive Summary

Given serious safety questions with tanezumab, the US filing seemed like throwing a Hail Mary; two FDA advisory panels overwhelmingly rejected the proposed risk management plan.

You may also be interested in...



Pfizer’s Tanezumab REMS Faces US FDA Doubts Heading Into Panel Review

Measures aimed at mitigating risk of progressive joint damage with the first-in-class nerve growth factor inhibitor may not be clinically feasible to implement or prevent rapid progression of osteoarthritis, FDA reviewers say; agency briefing document describes efficacy as 'modest' and says the sponsor's patient preference study was flawed and 'uninformative.'

Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III

Pfizer and Lilly plan to resume Phase III testing of their nerve growth factor inhibitor after FDA lifted a partial hold on tanezumab. But J&J is also poised to run new Phase III studies with fulranumab.

Pfizer forced to discontinue more trials for novel pain drug tanezumab

Pfizer is facing further disappointment with its promising first-in-class nerve growth factor (NGF) inhibitor, tanezumab. It has been forced by the US FDA to suspend clinical trials of the agent in chronic low back pain and painful diabetic peripheral neuropathy, following the recent suspension of the lead osteoarthritis programme due to safety concerns.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel